Study Group: Biostatisticians (US)
Council Members in this Study Group: 254
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Jed Gorlin
Transfusion Service Director
HENNEPIN HEALTHCARE SYSTEM INC
Jed Gorlin, MD, MBA, is the Medical Director of the Memorial Blood Center of Minnesota and an Associate Professor of Laboratory Medicine and Pediatrics at the University of Minnesota. Dr. Gorlin is also the Transfusion Services Director at Hennepin County...
Charles GlueckMedical Research Director of Cholesterol Center
Jewish HospitalCharles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology,...
- William Shannon
Founder and President
BioRankings, LLCWilliam Shannon, PhD, is an Associate Professor of Biostatistics at Washington University School of Medicine, since 1995; and Founder and President of BioRankings, a pharma IT firm, since January 2007. Dr. Shannon has over 20 years of applied biostatistical...
- Alfred Bartolucci
Professor
UNIVERSITY OF ALABAMA AT BIRMINGHAMAlfred Bartolucci, PhD, is a Professor of Biostatistics at University of Alabama at Birmingham. Dr. Bartolucci’s areas of expertise in applied statistics are oncology , Alzheimer's disease, cardiovascular disease, statistical genetic association research,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Meta-analysis of probiotics in atopic dermatitis
April 16, 2009
Analysis by: William Shannon, Founder and President,Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. | www.ncbi.nlm.nih.gov
The use of meta-analysis to evaluate probiotics in this condition is commendable. The abstract suggests that improvement may be real, but the evidence presented indicates that probiotics may be ineffective on careful reading. The abstract is lacking information needed to determine the quality of the meta-analysis and whether its results/suggestions should be considered in investment decisions.
-
New FDA effort takes aim at genomics: Inherent risk to investors
February 6, 2009
Analysis by: William Shannon, Founder and President,New FDA Effort to Take Aim at Genomics | www.genomeweb.com
The risk to an investor in genomic or personalized medicine is significant and a clear understanding of the low power and high risk of false-positives needs to be kept in mind. The establishment at the FDA of a senior scientist to oversee and coordinate genomic activities is necessary but not necessarily sufficient to insure that future genomic treatments are effective.
-
Eli Lilly's Personal Medicine Goal
November 27, 2008
Analysis by: William Shannon, Founder and President,Personal medicine is goal of Eli Lilly & Co. | www.azcentral.com
The Chairman of Eli Lilly announcing that personalized medicine (e.g., pharmacogenetics) is a major shift in strategy for big pharma could impact in a significant way the market share for new drugs and the amount of money for research needed to bring a targeted therapy to market. If this strategy is widely accepted the likely impact on small biotech firms will be a significant increase in their value and more acquisitions.
-
Dealing with publication bias using the 'file drawer' scenario.
October 28, 2008
Analysis by: William Shannon, Founder and President,Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
In this meta-analysis, the authors looked at the number of studies, if any, per new drug application with the FDA that got published, at what time, and how much information they released. They concluded that there is strong evidence of publication bias in what the drug companies will make public, with only 76% of pivotal trials and 24% of non-pivotal trials making publication. We looked at how this publication bias can affect investors when making investment decisions about pharmaceutical companies, due to limited or incomplete public information.
-
Is Biodel's argument to drop the India data from analysis valid?
October 9, 2008
Analysis by: William Shannon, Founder and President,Biodel Releases Preliminary Phase III Clinical Trials for VIAject | www.fiercebiotech.com
Biodel’s September 8th announcement of the Phase III non-inferiority trial results for VIAject at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome left many investors wary of the legitimacy of the data that was presented. The study, which was originally conducted in the US, Germany, and India, did not include the data from the Type 1 study in India in its final results due to the company’s claims of data anomalies that question the validity of the data for determining non-inferiority. We analyzed the study design and subgroup analyses to understand the impact of eliminating the India subgroup on the final trial results.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Professor
- Research Scientist
- Director
- Assistant Professor
- Researcher
- President
- Physician - Director
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Biostatisticians | 381 |
| Oncologists (US) | 2241 |
| General Cardiologists (US) | 1327 |
| Infectious Diseases Physicians (US) | 885 |
| Pathologists (US) | 792 |
| Emergency Medicine Physicians (US) | 1143 |
| Obstetricians/Gynecologists (US) | 1403 |
| Obstetricians/Gynecologists | 1947 |
GLG Live Meetings with this Study Group's Leading Experts (?)
March 28, 2008 | Boston
GLGi: Lipid ManagementGLG Webcasts & Teleconferences
Leading Experts in Biostatisticians (US) have not participated in any GLG webcasts.